Volker Arolt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3566575/publications.pdf

Version: 2024-02-01

300 papers 21,476 citations

74 h-index 127 g-index

309 all docs 309 docs citations

309 times ranked 25335 citing authors

#	Article	IF	CITATIONS
1	Chemokine receptor 4 expression on blood T lymphocytes predicts severity of major depressive disorder. Journal of Affective Disorders, 2022, 310, 343-353.	2.0	5
2	Genome-wide association study of panic disorder reveals genetic overlap with neuroticism and depression. Molecular Psychiatry, 2021, 26, 4179-4190.	4.1	58
3	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. Brain, Behavior, and Immunity, 2021, 91, 673-682.	2.0	15
4	Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease. Acta Neuropsychiatrica, 2021, 33, 22-30.	1.0	14
5	The endocannabinoid system in humans: significant associations between anandamide, brain function during reward feedback and a personality measure of reward dependence. Neuropsychopharmacology, 2021, 46, 1020-1027.	2.8	5
6	Variation of HbA1c affects cognition and white matter microstructure in healthy, young adults. Molecular Psychiatry, 2021, 26, 1399-1408.	4.1	27
7	Understanding the multidimensional phenomenon of medication adherence attitudes in psychosis. Psychiatry Research, 2021, 295, 113601.	1.7	4
8	Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis. European Neuropsychopharmacology, 2021, 44, 105-120.	0.3	5
9	Activation and deactivation steps in the tryptophan breakdown pathway in major depressive disorder: A link to the monocyte inflammatory state of patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110226.	2.5	12
10	Systematic misestimation of machine learning performance in neuroimaging studies of depression. Neuropsychopharmacology, 2021, 46, 1510-1517.	2.8	60
11	Efficacy of temporally intensified exposure for anxiety disorders: A multicenter randomized clinical trial. Depression and Anxiety, 2021, 38, 1169-1181.	2.0	19
12	Transfer of exposure therapy effects to a threat context not considered during treatment in patients with panic disorder and agoraphobia: Implications for potential mechanisms of change. Behaviour Research and Therapy, 2021, 142, 103886.	1.6	5
13	Neural adaptation of cingulate and insular activity during delayed fear extinction: A replicable pattern across assessment sites and repeated measurements. Neurolmage, 2021, 237, 118157.	2.1	13
14	The Genetic Architecture of Depression in Individuals of East Asian Ancestry. JAMA Psychiatry, 2021, 78, 1258.	6.0	88
15	Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110391.	2.5	43
16	Cortical surface area alterations shaped by genetic load for neuroticism. Molecular Psychiatry, 2020, 25, 3422-3431.	4.1	20
17	Influence of electroconvulsive therapy on white matter structure in a diffusion tensor imaging study. Psychological Medicine, 2020, 50, 849-856.	2.7	26
18	Depressive symptoms and health care within 30†days after discharge from a cardiac hospital unit: Response letter to the editor. General Hospital Psychiatry, 2020, 62, 100-101.	1.2	0

#	Article	IF	Citations
19	Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. Molecular Psychiatry, 2020, 25, 2355-2372.	4.1	22
20	Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression. Biological Psychiatry, 2020, 87, 419-430.	0.7	27
21	The role ofBDNFmethylation and Val66Met in amygdala reactivity during emotion processing. Human Brain Mapping, 2020, 41, 594-604.	1.9	14
22	Affective temperaments (TEMPS-A) in panic disorder and healthy probands: Genetic modulation by 5-HTT variation. World Journal of Biological Psychiatry, 2020, 21, 790-796.	1.3	9
23	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 921-932.	1.8	22
24	Effect of CBT on Biased Semantic Network in Panic Disorder: A Multicenter fMRI Study Using Semantic Priming. American Journal of Psychiatry, 2020, 177, 254-264.	4.0	19
25	Anxiety disorders and post-traumatic stress disorder in patients with coronary heart disease. Journal of Affective Disorders Reports, 2020, 1, 100009.	0.9	3
26	Depression and suicidality: A link to premature T helper cell aging and increased Th17 cells. Brain, Behavior, and Immunity, 2020, 87, 603-609.	2.0	57
27	The modulating impact of cigarette smoking on brain structure in panic disorder: a voxel-based morphometry study. Social Cognitive and Affective Neuroscience, 2020, 15, 849-859.	1.5	7
28	Association of 5-HTTLPR/rs25531 with depressive symptoms in patients with coronary heart disease: A prospective study. Journal of Affective Disorders, 2020, 277, 531-539.	2.0	2
29	Association of FKBP5 genotype with depressive symptoms in patients with coronary heart disease: a prospective study. Journal of Neural Transmission, 2020, 127, 1651-1662.	1.4	8
30	Brain structural correlates of alexithymia in patients with major depressive disorder. Journal of Psychiatry and Neuroscience, 2020, 45, 117-124.	1.4	8
31	Neural correlates of NOS1 ex1f-VNTR allelic variation in panic disorder and agoraphobia during fear conditioning and extinction in fMRI. NeuroImage: Clinical, 2020, 27, 102268.	1.4	1
32	An investigation of genetic variability of DNA methyltransferases DNMT3A and 3B does not provide evidence for a major role in the pathogenesis of panic disorder and dimensional anxiety phenotypes. Journal of Neural Transmission, 2020, 127, 1527-1537.	1.4	2
33	Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 803-818.	1.8	59
34	Association between heart-focused anxiety, depressive symptoms, health behaviors and healthcare utilization in patients with coronary heart disease. Journal of Psychosomatic Research, 2020, 131, 109958.	1.2	21
35	Biological sex classification with structural MRI data shows increased misclassification in transgender women. Neuropsychopharmacology, 2020, 45, 1758-1765.	2.8	14
36	An Investigation of Psychosis Subgroups With Prognostic Validation and Exploration of Genetic Underpinnings. JAMA Psychiatry, 2020, 77, 523.	6.0	39

3

#	Article	IF	Citations
37	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. Bipolar Disorders, 2019, 21, 68-75.	1.1	20
38	Structural and functional neural correlates of vigilant and avoidant regulation style. Journal of Affective Disorders, 2019, 258, 96-101.	2.0	3
39	Hypermethylation of the serotonin transporter gene promoter in panic disorder–Epigenetic imprint of comorbid depression?. European Neuropsychopharmacology, 2019, 29, 1161-1167.	0.3	16
40	Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. Frontiers in Psychiatry, 2019, 10, 458.	1.3	111
41	Association of rs7688285 allelic variation coding for GLRB with fear reactivity and exposure-based therapy in patients with panic disorder and agoraphobia. European Neuropsychopharmacology, 2019, 29, 1138-1151.	0.3	4
42	Association of NPSR1 gene variation and neural activity in patients with panic disorder and agoraphobia and healthy controls. NeuroImage: Clinical, 2019, 24, 102029.	1.4	8
43	Prevalence, 12-Month Prognosis, and Clinical Management Need of Depression in Coronary Heart Disease Patients: A Prospective Cohort Study. Psychotherapy and Psychosomatics, 2019, 88, 300-311.	4.0	30
44	Mediation of the influence of childhood maltreatment on depression relapse by cortical structure: a 2-year longitudinal observational study. Lancet Psychiatry, the, 2019, 6, 318-326.	3.7	97
45	Noninvasive Stimulation of the Ventromedial Prefrontal Cortex Indicates Valence Ambiguity in Sad Compared to Happy and Fearful Face Processing. Frontiers in Behavioral Neuroscience, 2019, 13, 83.	1.0	17
46	The effects of processing speed on memory impairment in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 494-500.	2.5	30
47	Association of Whole-Genome and NETRIN1 Signaling Pathway–Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 91-100.	1.1	16
48	The impact of depressive comorbidity on neural plasticity following cognitive-behavioral therapy in panic disorder with agoraphobia. Journal of Affective Disorders, 2019, 245, 451-460.	2.0	12
49	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. Journal of Neural Transmission, 2019, 126, 35-45.	1.4	27
50	Clinical and Neurofunctional Substrates of Cognitive Behavioral Therapy on Secondary Social Anxiety Disorder in Primary Panic Disorder: A Longitudinal fMRI Study. Psychotherapy and Psychosomatics, 2019, 88, 48-51.	4.0	1
51	Depressive symptoms and health care within 30 days after discharge from a cardiac hospital unit. General Hospital Psychiatry, 2019, 56, 19-27.	1.2	6
52	Childhood maltreatment moderates the influence of genetic load for obesity on reward related brain structure and function in major depression. Psychoneuroendocrinology, 2019, 100, 18-26.	1.3	17
53	Does prior traumatization affect the treatment outcome of CBT for panic disorder? The potential role of the MAOA gene and depression symptoms. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 161-170.	1.8	4
54	Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience, 2019, 22, 343-352.	7.1	1,589

#	Article	IF	CITATIONS
55	Time heals all wounds? A 2-year longitudinal diffusion tensor imaging study in major depressive disorder. Journal of Psychiatry and Neuroscience, 2019, 44, 407-413.	1.4	7
56	The relationship between social cognition and executive function in Major Depressive Disorder in high-functioning adolescents and young adults. Psychiatry Research, 2018, 263, 139-146.	1.7	20
57	Effects of cumulative illness severity on hippocampal gray matter volume in major depression: a voxel-based morphometry study. Psychological Medicine, 2018, 48, 2391-2398.	2.7	35
58	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics, 2018, 50, 668-681.	9.4	2,224
59	Noninvasive stimulation of the ventromedial prefrontal cortex modulates emotional face processing. Neurolmage, 2018, 175, 388-401.	2.1	33
60	Association of Brain Cortical Changes With Relapse in Patients With Major Depressive Disorder. JAMA Psychiatry, 2018, 75, 484.	6.0	60
61	The circulating levels of CD4+ t helper cells are higher in bipolar disorder as compared to major depressive disorder. Journal of Neuroimmunology, 2018, 319, 28-36.	1.1	42
62	Pretreatment Cardiac Vagal Tone Predicts Dropout from and Residual Symptoms after Exposure Therapy in Patients with Panic Disorder and Agoraphobia. Psychotherapy and Psychosomatics, 2018, 87, 187-189.	4.0	23
63	Elevated body-mass index is associated with reduced white matter integrity in two large independent cohorts. Psychoneuroendocrinology, 2018, 91, 179-185.	1.3	55
64	The Limbic System in Youth Depression: Brain Structural and Functional Alterations in Adolescent In-patients with Severe Depression. Neuropsychopharmacology, 2018, 43, 546-554.	2.8	67
65	Does Childhood Trauma Moderate Polygenic Risk for Depression? A Meta-analysis of 5765 Subjects From the Psychiatric Genomics Consortium. Biological Psychiatry, 2018, 84, 138-147.	0.7	87
66	Altered B Cell Homeostasis in Patients with Major Depressive Disorder and Normalization of CD5 Surface Expression on Regulatory B Cells in Treatment Responders. Journal of NeuroImmune Pharmacology, 2018, 13, 90-99.	2.1	37
67	Association of Serotonin Transporter Gene AluJb Methylation with Major Depression, Amygdala Responsiveness, 5-HTTLPR/rs25531 Polymorphism, and Stress. Neuropsychopharmacology, 2018, 43, 1308-1316.	2.8	73
68	Effects of Cognitive Behavioral Therapy on Neural Processing of Agoraphobia-Specific Stimuli in Panic Disorder and Agoraphobia. Psychotherapy and Psychosomatics, 2018, 87, 350-365.	4.0	7
69	Alterations of the Innate Immune System in Susceptibility and Resilience After Social Defeat Stress. Frontiers in Behavioral Neuroscience, 2018, 12, 141.	1.0	41
70	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 65.	1.3	38
71	Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Biological Psychiatry, 2017, 81, 325-335.	0.7	175
72	Serum brain-derived neurotrophic factor and stability of depressive symptoms in coronary heart disease patients: A prospective study. Psychoneuroendocrinology, 2017, 77, 196-202.	1.3	20

#	Article	IF	CITATIONS
73	Differential Abnormal Pattern of Anterior Cingulate Gyrus Activation in Unipolar and Bipolar Depression: an fMRI and Pattern Classification Approach. Neuropsychopharmacology, 2017, 42, 1399-1408.	2.8	61
74	CRHR1 promoter hypomethylation: An epigenetic readout of panic disorder?. European Neuropsychopharmacology, 2017, 27, 360-371.	0.3	46
75	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	2.5	71
76	The importance of strengthening competence and control beliefs in patients with psychosis to reduce treatment hindering self-stigmatization. Psychiatry Research, 2017, 255, 314-320.	1.7	11
77	Optimizing exposure-based CBT for anxiety disorders via enhanced extinction: Design and methods of a multicentre randomized clinical trial. International Journal of Methods in Psychiatric Research, 2017, 26, e1560.	1.1	37
78	Serum brain-derived neurotrophic factor and depressive symptoms in coronary heart disease patients: Role of cognitive functions. Psychoneuroendocrinology, 2017, 79, 175-176.	1.3	2
79	Commonalities and differences in the neural substrates of threat predictability in panic disorder and specific phobia. NeuroImage: Clinical, 2017, 14, 530-537.	1.4	17
80	Childhood adversity impacts on brain subcortical structures relevant to depression. Journal of Psychiatric Research, 2017, 86, 58-65.	1.5	81
81	Neurobiological and clinical effects of fNIRS-controlled rTMS in patients with panic disorder/agoraphobia during cognitive-behavioural therapy. Neurolmage: Clinical, 2017, 16, 668-677.	1.4	29
82	The effect of childhood trauma on serum BDNF in bipolar depression is modulated by the serotonin promoter genotype. Neuroscience Letters, 2017, 656, 177-181.	1.0	17
83	Chemokine CCL17 is expressed by dendritic cells in the CNS during experimental autoimmune encephalomyelitis and promotes pathogenesis of disease. Brain, Behavior, and Immunity, 2017, 66, 382-393.	2.0	50
84	Diagnostic classification of unipolar depression based on resting-state functional connectivity MRI: effects of generalization to a diverse sample. Journal of Neural Transmission, 2017, 124, 589-605.	1.4	24
85	Human subcortical brain asymmetries in 15,847 people worldwide reveal effects of age and sex. Brain Imaging and Behavior, 2017, 11, 1497-1514.	1.1	144
86	High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib. Frontiers in Psychiatry, 2017, 8, 16.	1.3	33
87	Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia. Frontiers in Psychiatry, 2017, 8, 99.	1.3	24
88	Prefrontal brain responsiveness to negative stimuli. Journal of Psychiatry and Neuroscience, 2017, 42, 343-352.	1.4	24
89	Hypermethylation of FOXP3 Promoter and Premature Aging of the Immune System in Female Patients with Panic Disorder?. PLoS ONE, 2016, 11, e0157930.	1.1	15
90	Molecular serum signature of treatment resistant depression. Psychopharmacology, 2016, 233, 3051-3059.	1.5	20

#	Article	IF	Citations
91	Major depressive disorder: Findings of reduced homotopic connectivity and investigation of underlying structural mechanisms. Human Brain Mapping, 2016, 37, 1209-1217.	1.9	47
92	Prepare for scareâ€"Impact of threat predictability on affective visual processing in spider phobia. Behavioural Brain Research, 2016, 307, 84-91.	1.2	9
93	The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. Journal of Anxiety Disorders, 2016, 42, 10-18.	1.5	14
94	Prediction of Individual Response to Electroconvulsive Therapy via Machine Learning on Structural Magnetic Resonance Imaging Data. JAMA Psychiatry, 2016, 73, 557.	6.0	257
95	Stem Cell Factor (SCF) is a putative biomarker of antidepressant response. Journal of NeuroImmune Pharmacology, 2016, 11, 248-258.	2.1	28
96	Reduced locomotor activity and exploratory behavior in CC chemokine receptor 4 deficient mice. Behavioural Brain Research, 2016, 314, 87-95.	1.2	18
97	Cytokine levels in major depression are related to childhood trauma but not to recent stressors. Psychoneuroendocrinology, 2016, 73, 24-31.	1.3	81
98	Impact of major depressive disorder, distinct subtypes, and symptom severity on lifestyle in the BiDirect Study. Psychiatry Research, 2016, 245, 164-171.	1.7	18
99	Inflammatory cytokines influence measures of white matter integrity in Bipolar Disorder. Journal of Affective Disorders, 2016, 202, 1-9.	2.0	125
100	Emotional processing and rTMS: does inhibitory theta burst stimulation affect the human startle reflex?. Journal of Neural Transmission, 2016, 123, 1121-1131.	1.4	3
101	Neural correlates of individual differences in anxiety sensitivity: an fMRI study using semantic priming. Social Cognitive and Affective Neuroscience, 2016, 11, 1245-1254.	1.5	16
102	Prenatal immune activation in mice blocks the effects of environmental enrichment on exploratory behavior and microglia density. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 67, 10-20.	2.5	33
103	Impact of electroconvulsive therapy on magnetoencephalographic correlates of dysfunctional emotional processing in major depression. European Neuropsychopharmacology, 2016, 26, 684-692.	0.3	13
104	Facing the fear – clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. European Neuropsychopharmacology, 2016, 26, 431-444.	0.3	19
105	Disadvantage of Social Sensitivity: Interaction of Oxytocin Receptor Genotype and Child Maltreatment on Brain Structure. Biological Psychiatry, 2016, 80, 398-405.	0.7	69
106	Deficiencies of the T and natural killer cell system in major depressive disorder. Brain, Behavior, and Immunity, 2016, 54, 38-44.	2.0	133
107	Die Effekte interozeptiver Expositionsý bungen in der Kognitiven Verhaltenstherapie von Panikstörung mit Agoraphobie. Verhaltenstherapie, 2015, 25, 268-276.	0.3	6
108	SPIDER OR NO SPIDER? NEURAL CORRELATES OF SUSTAINED AND PHASIC FEAR IN SPIDER PHOBIA. Depression and Anxiety, 2015, 32, 656-663.	2.0	53

#	Article	IF	Citations
109	Reward Processing in Unipolar and Bipolar Depression: A Functional MRI Study. Neuropsychopharmacology, 2015, 40, 2623-2631.	2.8	136
110	Evidence of an IFN- \hat{l}^3 by early life stress interaction in the regulation of amygdala reactivity to emotional stimuli. Psychoneuroendocrinology, 2015, 62, 166-173.	1.3	33
111	Oxytocin Receptor Gene Methylation: Converging Multilevel Evidence for a Role in Social Anxiety. Neuropsychopharmacology, 2015, 40, 1528-1538.	2.8	155
112	Multilevel impact of the dopamine system on the emotion-potentiated startle reflex. Psychopharmacology, 2015, 232, 1983-1993.	1.5	10
113	Enhanced neural responsiveness to reward associated with obesity in the absence of foodâ€related stimuli. Human Brain Mapping, 2015, 36, 2330-2337.	1.9	47
114	Therapygenetics: anterior cingulate cortex–amygdala coupling is associated with 5-HTTLPR and treatment response in panic disorder with agoraphobia. Journal of Neural Transmission, 2015, 122, 135-144.	1.4	31
115	Neuropeptide S receptor gene variation modulates anterior cingulate cortex Glx levels during CCK-4 induced panic. European Neuropsychopharmacology, 2015, 25, 1677-1682.	0.3	17
116	Separating depressive comorbidity from panic disorder: A combined functional magnetic resonance imaging and machine learning approach. Journal of Affective Disorders, 2015, 184, 182-192.	2.0	45
117	Predicting Treatment Response to Cognitive Behavioral Therapy in Panic Disorder With Agoraphobia by Integrating Local Neural Information. JAMA Psychiatry, 2015, 72, 68.	6.0	110
118	Are you gonna leave me? Separation anxiety is associated with increased amygdala responsiveness and volume. Social Cognitive and Affective Neuroscience, 2015, 10, 278-284.	1.5	57
119	NCAN Cross-Disorder Risk Variant Is Associated With Limbic Gray Matter Deficits in Healthy Subjects and Major Depression. Neuropsychopharmacology, 2015, 40, 2510-2516.	2.8	56
120	The cannabinoid receptor 2 is involved in acute rejection of cardiac allografts. Life Sciences, 2015, 138, 29-34.	2.0	10
121	Monocyte activation, brainâ€derived neurotrophic factor (<scp>BDNF</scp>), and S100B in bipolar offspring: a followâ€up study from adolescence into adulthood. Bipolar Disorders, 2015, 17, 39-49.	1.1	40
122	Obesity and major depression: Body-mass index (BMI) is associated with a severe course of disease and specific neurostructural alterations. Psychoneuroendocrinology, 2015, 51, 219-226.	1.3	120
123	Clinical characteristics of inflammation-associated depression: Monocyte gene expression is age-related in major depressive disorder. Brain, Behavior, and Immunity, 2015, 44, 48-56.	2.0	59
124	Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response. Journal of Neural Transmission, 2015, 122, 99-108.	1.4	46
125	Assessment and follow-up of suicidal ideation when screening for depression in hospitalized coronary heart disease patients – development of a protocol. European Journal for Person Centered Healthcare, 2015, 3, 523.	0.3	1
126	Insular and Hippocampal Gray Matter Volume Reductions in Patients with Major Depressive Disorder. PLoS ONE, 2014, 9, e102692.	1.1	138

#	Article	IF	CITATIONS
127	Influence of Repressive Coping Style on Cortical Activation during Encoding of Angry Faces. PLoS ONE, 2014, 9, e112398.	1.1	5
128	Brain Morphometric Biomarkers Distinguishing Unipolar and Bipolar Depression. JAMA Psychiatry, 2014, 71, 1222.	6.0	226
129	Hippocampal Atrophy in Major Depression: a Function of Childhood Maltreatment Rather than Diagnosis?. Neuropsychopharmacology, 2014, 39, 2723-2731.	2.8	158
130	Have we met before? Neural correlates of emotional learning in women with social phobia. Journal of Psychiatry and Neuroscience, 2014, 39, E14-E23.	1.4	10
131	Amygdala excitability to subliminally presented emotional faces distinguishes unipolar and bipolar depression: An fMRI and pattern classification study. Human Brain Mapping, 2014, 35, 2995-3007.	1.9	99
132	Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. International Journal of Neuropsychopharmacology, 2014, 17, 1167-1176.	1.0	146
133	Association of Adenosine Receptor Gene Polymorphisms and In Vivo Adenosine A1 Receptor Binding in The Human Brain. Neuropsychopharmacology, 2014, 39, 2989-2999.	2.8	29
134	Neural Correlates of Procedural Variants in Cognitive-Behavioral Therapy: A Randomized, Controlled Multicenter fMRI Study. Psychotherapy and Psychosomatics, 2014, 83, 222-233.	4.0	31
135	Impaired spatial learning and reduced adult hippocampal neurogenesis in histamine H1-receptor knockout mice. European Neuropsychopharmacology, 2014, 24, 1394-1404.	0.3	28
136	No evidence of DISC1-associated morphological changes in the hippocampus, anterior cingulate cortex, or striatum in major depressive disorder cases and healthy controls. Journal of Affective Disorders, 2014, 166, 103-107.	2.0	7
137	GENDER-SPECIFIC ASSOCIATION OF VARIANTS IN THE <i> AKR1C1 < /i > GENE WITH DIMENSIONAL ANXIETY IN PATIENTS WITH PANIC DISORDER: ADDITIONAL EVIDENCE FOR THE IMPORTANCE OF NEUROSTEROIDS IN ANXIETY?. Depression and Anxiety, 2014, 31, 843-850.</i>	2.0	15
138	Neuropeptide S receptor gene ($\langle i \rangle$ NPSR $\langle i \rangle$) and life events: G $\tilde{A}-$ E effects on anxiety sensitivity and its subdimensions. World Journal of Biological Psychiatry, 2014, 15, 17-25.	1.3	56
139	MANIAâ€"A Pattern Classification Toolbox for Neuroimaging Data. Neuroinformatics, 2014, 12, 471-486.	1.5	21
140	Serotonin transporter gene methylation is associated with hippocampal gray matter volume. Human Brain Mapping, 2014, 35, 5356-5367.	1.9	53
141	Social Alienation in Schizophrenia Patients: Association with Insula Responsiveness to Facial Expressions of Disgust. PLoS ONE, 2014, 9, e85014.	1.1	30
142	Of  Disgrace' and  Pain' – Corticolimbic Interaction Patterns for Disorder-Relevant and Emotional Words in Social Phobia. PLoS ONE, 2014, 9, e109949.	1.1	14
143	Childhood maltreatment is associated with an automatic negative emotion processing bias in the amygdala. Human Brain Mapping, 2013, 34, 2899-2909.	1.9	207
144	Discriminating unipolar and bipolar depression by means of fMRI and pattern classification: a pilot study. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 119-131.	1.8	88

#	Article	IF	Citations
145	S100B overexpression increases behavioral and neural plasticity in response to the social environment during adolescence. Journal of Psychiatric Research, 2013, 47, 1791-1799.	1.5	22
146	Neuropeptide S receptor (NPSR1) gene variation modulates response inhibition and error monitoring. NeuroImage, 2013, 71, 1-9.	2.1	35
147	Neural Substrates of Treatment Response to Cognitive-Behavioral Therapy in Panic Disorder With Agoraphobia. American Journal of Psychiatry, 2013, 170, 1345-1355.	4.0	120
148	Acute anxiolytic effects of quetiapine during virtual reality exposureâ€"A double-blind placebo-controlled trial in patients with specific phobia. European Neuropsychopharmacology, 2013, 23, 1551-1560.	0.3	23
149	Associations between cognitive performance and cortisol reaction to the DEX/CRH test in patients recovered from depression. Psychoneuroendocrinology, 2013, 38, 447-454.	1.3	24
150	Epigenetic signature of panic disorder: A role of glutamate decarboxylase 1 (GAD1) DNA hypomethylation?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 189-196.	2.5	62
151	Effect of Cognitive-Behavioral Therapy on Neural Correlates of Fear Conditioning in Panic Disorder. Biological Psychiatry, 2013, 73, 93-101.	0.7	137
152	Alexithymia is related to differences in gray matter volume: A voxel-based morphometry study. Brain Research, 2013, 1491, 60-67.	1.1	56
153	Effects of ADORA2A gene variation and caffeine on prepulse inhibition: A multi-level risk model of anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 115-121.	2.5	37
154	Craving in Alcohol-Dependent Patients After Detoxification Is Related to Glutamatergic Dysfunction in the Nucleus Accumbens and the Anterior Cingulate Cortex. Neuropsychopharmacology, 2013, 38, 1401-1408.	2.8	110
155	The mirror neuron system under hypnosis – Brain substrates of voluntary and involuntary motor activation in hypnotic paralysis. Cortex, 2013, 49, 437-445.	1.1	18
156	Dopamine D3 receptor gene variation: impact on electroconvulsive therapy response and ventral striatum responsiveness in depression. International Journal of Neuropsychopharmacology, 2013, 16, 1443-1459.	1.0	26
157	Acute Shift in Glutamate Concentrations Following Experimentally Induced Panic with Cholecystokinin Tetrapeptide—A 3T-MRS Study in Healthy Subjects. Neuropsychopharmacology, 2013, 38, 1648-1654.	2.8	31
158	Evidence of increased risk for major depressive disorder in individuals homozygous for the high-expressing 5-HTTLPR/rs25531 (LA) allele of the serotonin transporter promoter. Psychiatric Genetics, 2013, 23, 222-223.	0.6	7
159	Mood-congruent amygdala responses to subliminally presented facial expressions in major depression: associations with anhedonia. Journal of Psychiatry and Neuroscience, 2013, 38, 249-258.	1.4	88
160	Effect of Acute Stressor and Serotonin Transporter Genotype on Amygdala First Wave Transcriptome in Mice. PLoS ONE, 2013, 8, e58880.	1.1	11
161	Possible Associations of NTRK2 Polymorphisms with Antidepressant Treatment Outcome: Findings from an Extended Tag SNP Approach. PLoS ONE, 2013, 8, e64947.	1.1	17
162	Genome-Wide Association Study of Antidepressant Treatment-Emergent Suicidal Ideation. Neuropsychopharmacology, 2012, 37, 797-807.	2.8	76

#	Article	IF	CITATIONS
163	Depression Does Not Affect the Treatment Outcome of CBT for Panic and Agoraphobia: Results from a Multicenter Randomized Trial. Psychotherapy and Psychosomatics, 2012, 81, 161-172.	4.0	36
164	Diagnosing Delirium in Older Hospitalized Adults with Dementia: Adapting the Confusion Assessment Method to <i>International Classification of Diseases, Tenth Revision</i> , Diagnostic Criteria. Journal of the American Geriatrics Society, 2012, 60, 1471-1477.	1.3	59
165	Anterior cingulate cortex activation is related to learning potential on the WCST in schizophrenia patients. Brain and Cognition, 2012, 79, 245-251.	0.8	28
166	Limbic Scars: Long-Term Consequences of Childhood Maltreatment Revealed by Functional and Structural Magnetic Resonance Imaging. Biological Psychiatry, 2012, 71, 286-293.	0.7	789
167	Dynamics of Defensive Reactivity in Patients with Panic Disorder and Agoraphobia: Implications for the Etiology of Panic Disorder. Biological Psychiatry, 2012, 72, 512-520.	0.7	69
168	Tumor Necrosis Factor Gene Variation Predicts Hippocampus Volume in Healthy Individuals. Biological Psychiatry, 2012, 72, 655-662.	0.7	64
169	Moderators of the relationship between depression and cardiovascular disorders: a systematic review. General Hospital Psychiatry, 2012, 34, 478-492.	1.2	49
170	Catechol-O-methyltransferase gene variation: Impact on amygdala response to aversive stimuli. Neurolmage, 2012, 60, 2222-2229.	2.1	63
171	ADORA2A Gene Variation, Caffeine, and Emotional Processing: A Multi-level Interaction on Startle Reflex. Neuropsychopharmacology, 2012, 37, 759-769.	2.8	52
172	Gender Differences in Associations of Glutamate Decarboxylase 1 Gene (GAD1) Variants with Panic Disorder. PLoS ONE, 2012, 7, e37651.	1.1	20
173	Affect-Modulated Startle: Interactive Influence of Catechol-O-Methyltransferase Val158Met Genotype and Childhood Trauma. PLoS ONE, 2012, 7, e39709.	1.1	21
174	Monoamine oxidase A gene DNA hypomethylation $\hat{a} \in \hat{a}$ a risk factor for panic disorder? International Journal of Neuropsychopharmacology, 2012, 15, 1217-1228.	1.0	100
175	Modification of caffeine effects on the affect-modulated startle by neuropeptide S receptor gene variation. Psychopharmacology, 2012, 222, 533-541.	1.5	22
176	KPNA3 variation is associated with schizophrenia, major depression, opiate dependence and alcohol dependence. Disease Markers, 2012, 33, 163-70.	0.6	11
177	Psychological treatment for panic disorder with agoraphobia: A randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT Journal of Consulting and Clinical Psychology, 2011, 79, 406-420.	1.6	189
178	Neuropeptide-S (NPS) Receptor Genotype Modulates Basolateral Amygdala Responsiveness to Aversive Stimuli. Neuropsychopharmacology, 2011, 36, 1879-1885.	2.8	85
179	Dysbindin (DTNBP1) – A role in psychotic depression?. Journal of Psychiatric Research, 2011, 45, 588-595.	1.5	22
180	Serotonin transporter gene and childhood trauma - a G $\tilde{A}-$ E effect on anxiety sensitivity. Depression and Anxiety, 2011, 28, 1048-1057.	2.0	58

#	Article	IF	Citations
181	Cross-Disorder Analysis of Bipolar Risk Genes: Further Evidence of DGKH as a Risk Gene for Bipolar Disorder, but also Unipolar Depression and Adult ADHD. Neuropsychopharmacology, 2011, 36, 2076-2085.	2.8	93
182	Adult attachment avoidance and automatic affective response to sad facial expressions. Australian Journal of Psychology, 2010, 62, 181-187.	1.4	19
183	Increased amygdala activation during automatic processing of facial emotion in schizophrenia. Psychiatry Research - Neuroimaging, 2010, 182, 200-206.	0.9	55
184	Persistent non-verbal memory impairment in remitted major depression â€" Caused by encoding deficits?. Journal of Affective Disorders, 2010, 122, 144-148.	2.0	61
185	ORIGINAL RESEARCHâ€"INTERSEX AND GENDER IDENTITY DISORDERS: Neuroimaging Differences in Spatial Cognition between Men and Male-to-Female Transsexuals Before and During Hormone Therapy. Journal of Sexual Medicine, 2010, 7, 1858-1867.	0.3	79
186	Neural correlates of set-shifting: decomposing executive functions in schizophrenia. Journal of Psychiatry and Neuroscience, 2010, 35, 321-329.	1.4	50
187	Norepinephrine and Serotonin Transporter Genes: Impact on Treatment Response in Depression. Neuropsychobiology, 2010, 62, 121-131.	0.9	63
188	Altered auditory processing in patients with panic disorder: A pilot study. World Journal of Biological Psychiatry, 2010, 11, 945-955.	1.3	17
189	Automatic Mood-Congruent Amygdala Responses to Masked Facial Expressions in Major Depression. Biological Psychiatry, 2010, 67, 155-160.	0.7	283
190	The Interleukin 1 Beta (IL1B) Gene Is Associated with Failure to Achieve Remission and Impaired Emotion Processing in Major Depression. Biological Psychiatry, 2010, 67, 543-549.	0.7	169
191	Theory of Mind in first-episode schizophrenia patients: Correlations with cognition and personality traits. Schizophrenia Research, 2010, 119, 115-123.	1.1	119
192	Individual differences in alexithymia and brain response to masked emotion faces. Cortex, 2010, 46, 658-667.	1.1	170
193	HTR2A gene variation is involved in antidepressant treatment response. European Neuropsychopharmacology, 2010, 20, 65-68.	0.3	71
194	Neuropeptide Y (NPY) gene: Impact on emotional processing and treatment response in anxious depression. European Neuropsychopharmacology, 2010, 20, 301-309.	0.3	95
195	Emotion specific modulation of automatic amygdala responses by 5-HTTLPR genotype. Neurolmage, 2010, 53, 893-898.	2.1	77
196	Impact of Working Memory Load on fMRI Resting State Pattern in Subsequent Resting Phases. PLoS ONE, 2009, 4, e7198.	1.1	97
197	The Effects of Dysthymic Disorder on Health-Related Quality of Life and Disability Days in Persons with Comorbid Medical Conditions in the General Population. Psychotherapy and Psychosomatics, 2009, 78, 161-166.	4.0	33
198	Neural Activation Underlying Acute Grief in Women After the Loss of an Unborn Child. American Journal of Psychiatry, 2009, 166, 1402-1410.	4.0	55

#	Article	IF	Citations
199	A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine. World Journal of Biological Psychiatry, 2009, 10, 609-611.	1.3	10
200	Reduced amygdala–prefrontal coupling in major depression: association with MAOA genotype and illness severity. International Journal of Neuropsychopharmacology, 2009, 12, 11.	1.0	195
201	Complicated grief in patients with unipolar depression. Journal of Affective Disorders, 2009, 118, 201-204.	2.0	42
202	Workingâ€memory fMRI reveals cingulate hyperactivation in euthymic major depression. Human Brain Mapping, 2009, 30, 2746-2756.	1.9	69
203	Attachment avoidance modulates neural response to masked facial emotion. Human Brain Mapping, 2009, 30, 3553-3562.	1.9	75
204	Association analysis of Rgs7 variants with panic disorder. Journal of Neural Transmission, 2009, 116, 1523-1528.	1.4	21
205	Psychological impact on women after second and third trimester termination of pregnancy due to fetal anomalies versus women after preterm birth—a 14-month follow up study. Archives of Women's Mental Health, 2009, 12, 193-201.	1.2	99
206	Implicit and explicit procedural learning in patients recently remitted from severe major depression. Psychiatry Research, 2009, 169, 1-6.	1.7	18
207	S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials. Neuropsychobiology, 2009, 59, 172-177.	0.9	10
208	Erratum to "Finding of abnormal scanning behavior in the Span of Apprehension task in schizophrenia but diagnostic non-specificity of sum scores―[Eur Psychiatry 23 (2008) 29–32]. European Psychiatry, 2009, 24, 63-63.	0.1	0
209	Human Fear Conditioning and Extinction in Neuroimaging: A Systematic Review. PLoS ONE, 2009, 4, e5865.	1.1	470
210	Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect?. Depression and Anxiety, 2008, 25, 920-925.	2.0	48
211	Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Human Psychopharmacology, 2008, 23, 587-593.	0.7	12
212	Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. Psychiatry Research - Neuroimaging, 2008, 163, 13-20.	0.9	93
213	Reduced implicit and explicit sequence learning in first-episode schizophrenia. Neuropsychologia, 2008, 46, 186-195.	0.7	31
214	Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophrenia Research, 2008, 106, 156-163.	1.1	63
215	Alexithymic features and automatic amygdala reactivity to facial emotion. Neuroscience Letters, 2008, 435, 40-44.	1.0	89
216	Association between IL-8 cytokine and cognitive performance in an elderly general population—The MEMO-Study. Neurobiology of Aging, 2008, 29, 937-944.	1.5	130

#	Article	IF	Citations
217	Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 224-228.	2.5	57
218	Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1789-1792.	2.5	44
219	Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in Major Depression. European Neuropsychopharmacology, 2008, 18, 751-759.	0.3	158
220	Finding of abnormal scanning behavior in the Span of Apprehension task in schizophrenia but diagnostic non-specificity of sum scores. European Psychiatry, 2008, 23, 29-32.	0.1	0
221	5-HTTLPR Biases Amygdala Activity in Response to Masked Facial Expressions in Major Depression. Neuropsychopharmacology, 2008, 33, 418-424.	2.8	156
222	Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression. Neuropsychopharmacology, 2008, 33, 924-932.	2.8	127
223	Therapeutic strategies for catatonia in paraneoplastic encephalitis. World Journal of Biological Psychiatry, 2008, 9, 236-240.	1.3	21
224	Association of MAO-A Variant with Complicated Grief in Major Depression. Neuropsychobiology, 2007, 56, 191-196.	0.9	30
225	Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 361-364.	2.5	72
226	fMRI amygdala activation during a spontaneous panic attack in a patient with panic disorder. World Journal of Biological Psychiatry, 2007, 8, 269-272.	1.3	65
227	Amygdala reactivity predicts automatic negative evaluations for facial emotions. Psychiatry Research - Neuroimaging, 2007, 154, 13-20.	0.9	103
228	Autocrine S100B effects on astrocytes are mediated via RAGE. Journal of Neuroimmunology, 2007, 184, 214-222.	1.1	94
229	The relationship between psychological dimensions of depressive symptoms and cognitive functioning in the elderly – The MEMO-Study. Journal of Psychiatric Research, 2007, 41, 247-254.	1.5	41
230	Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study. Journal of Psychiatric Research, 2007, 41, 625-634.	1.5	94
231	Threat sensitivity as assessed by automatic amygdala response to fearful faces predicts speed of visual search for facial expression. Experimental Brain Research, 2007, 183, 51-59.	0.7	32
232	Amygdala reactivity to masked negative faces is associated with automatic judgmental bias in major depression: a 3 T fMRI study. Journal of Psychiatry and Neuroscience, 2007, 32, 423-9.	1.4	93
233	Amygdala activation during masked presentation of emotional faces predicts conscious detection of threat-related faces. Brain and Cognition, 2006, 61, 243-248.	0.8	45
234	Evidence from increased anticipation of predictive saccades for a dysfunction of fronto-striatal circuits in obsessive–compulsive disorder. Psychiatry Research, 2006, 143, 77-88.	1.7	35

#	Article	IF	Citations
235	Subliminal affective priming in clinical depression and comorbid anxiety: A longitudinal investigation. Psychiatry Research, 2006, 143, 63-75.	1.7	30
236	Association of the functional [minus sign]1019C/G 5-HT 1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. International Journal of Neuropsychopharmacology, 2006, 9, 349.	1.0	116
237	Memory Performance in Severely Depressed Patients Treated by Electroconvulsive Therapy. Journal of ECT, 2006, 22, 189-195.	0.3	19
238	Masked facial affect priming is associated with therapy response in clinical depression. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 215-221.	1.8	41
239	Unimpaired automatic processing of verbal information in the course of clinical depression. Depression and Anxiety, 2006, 23, 325-330.	2.0	10
240	Associations between Major Depression, Bipolar Disorders, Dysthymia and Cardiovascular Diseases in the General Adult Population. Psychotherapy and Psychosomatics, 2006, 75, 319-326.	4.0	73
241	The Association between Depressive Mood and Cognitive Performance in an Elderly General Population – The MEMO Study. Dementia and Geriatric Cognitive Disorders, 2006, 22, 142-149.	0.7	50
242	Reduced Awareness of Others' Emotions in Unipolar Depressed Patients. Journal of Nervous and Mental Disease, 2005, 193, 331-337.	0.5	84
243	Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. Journal of Affective Disorders, 2005, 87, 305-311.	2.0	165
244	The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology, 2005, 178, 161-166.	1.5	84
245	Automatic processing of facial emotion in schizophrenia with and without affective negative symptoms. Cognitive Neuropsychiatry, 2005, 10, 35-56.	0.7	14
246	Basal Prolactin Values Correlate with Response to Reboxetine Treatment in Major Depression, but Not with Response to Citalopram. Neuropsychobiology, 2005, 51, 67-71.	0.9	9
247	Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophrenia Research, 2005, 73, 153-157.	1.1	92
248	Visual backward masking: Deficits in locating targets are specific to schizophrenia and not related to intellectual decline. Schizophrenia Research, 2005, 78, 261-268.	1.1	18
249	S100B Serum Levels and Long-Term Improvement of Negative Symptoms in Patients with Schizophrenia. Neuropsychopharmacology, 2004, 29, 1004-1011.	2.8	106
250	Search for atypical lymphocytes in schizophrenia. World Journal of Biological Psychiatry, 2004, 5, 33-37.	1.3	22
251	Spatial processing of facial emotion in patients with unipolar depression: a longitudinal study. Journal of Affective Disorders, 2004, 83, 59-63.	2.0	93
252	Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression. Neuroscience Letters, 2004, 354, 69-73.	1.0	34

#	Article	IF	CITATIONS
253	A brief diagnostic screening instrument for mental disturbances in general medical wards. Journal of Psychosomatic Research, 2004, 57, 17-24.	1.2	44
254	Proton magnetic resonance spectroscopy in anorexia nervosa: correlations with cognition. NeuroReport, 2004, 15, 549-553.	0.6	67
255	Prevalence of Psychiatric Disorders in Physically Ill Patients. , 2004, 26, 31-51.		7
256	Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology, 2003, 168, 344-346.	1.5	168
257	Affective priming in schizophrenia with and without affective negative symptoms. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 292-300.	1.8	49
258	Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Research - Neuroimaging, 2003, 122, 185-192.	0.9	266
259	S100B in brain damage and neurodegeneration. Microscopy Research and Technique, 2003, 60, 614-632.	1.2	506
260	Metabolic changes after repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal cortex: a sham-controlled proton magnetic resonance spectroscopy (1H MRS) study of healthy brain. European Journal of Neuroscience, 2003, 17, 2462-2468.	1.2	138
261	S100B and response to treatment in major depression: a pilot study. European Neuropsychopharmacology, 2003, 13, 235-239.	0.3	98
262	Detection of facial expressions of emotions in schizophrenia. Schizophrenia Research, 2003, 64, 137-145.	1.1	30
263	The experience of basic emotions in schizophrenia with and without affective negative symptoms. Comprehensive Psychiatry, 2003, 44, 303-310.	1.5	41
264	Automatic processing of verbal emotion stimuli in schizophrenia. Psychiatry Research, 2003, 120, 131-144.	1.7	22
265	Neurotrophic Effects of Electroconvulsive Therapy: A Proton Magnetic Resonance Study of the Left Amygdalar Region in Patients with Treatment-Resistant Depression. Neuropsychopharmacology, 2003, 28, 720-725.	2.8	186
266	DISSOCIATIVE DISORDERS AND TRAUMATIC CHILDHOOD EXPERIENCES IN TRANSSEXUALS. Journal of Nervous and Mental Disease, 2003, 191, 182-189.	0.5	40
267	Timing of psychoeducational psychotherapeutic interventions in schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience, 2002, 252, 115-119.	1.8	27
268	Vascular Endothelial Growth Factor Protects Cultured Rat Hippocampal Neurons against Hypoxic Injury via an Antiexcitotoxic, Caspase-Independent Mechanism. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1170-1175.	2.4	113
269	Review of Immunological and Immunopathological Findings in Schizophrenia. Brain, Behavior, and Immunity, 2001, 15, 319-339.	2.0	167
270	Care Complexity in the General Hospital Results From a European Study. Psychosomatics, 2001, 42, 204-212.	2.5	50

#	Article	IF	Citations
271	Risk Factors for Complex Care Needs in General Medical Inpatients: Results From a European Study. Psychosomatics, 2001, 42, 213-221.	2.5	43
272	COMPRIâ€"An Instrument to Detect Patients With Complex Care Needs: Results From a European Study. Psychosomatics, 2001, 42, 222-228.	2.5	76
273	The Influence of Familial Loading on the Course of Schizophrenic Symptoms and the Success of Psychoeducational Therapy. Psychopathology, 2001, 34, 192-197.	1.1	14
274	Traumatische Trauer - ein eigenstÄ ¤ diges Krankheitsbild?. Psychotherapeut, 2001, 46, 301-308.	0.1	20
275	Different immune patterns in melancholic and non-melancholic major depression. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 90-97.	1.8	127
276	Mental disturbances and perceived complexity of nursing care in medical inpatients: results from a European study. Journal of Advanced Nursing, 2001, 36, 355-363.	1.5	9
277	Inflammatory markers in major depression and melancholia. Journal of Affective Disorders, 2001, 63, 93-102.	2.0	161
278	S-100B is increased in melancholic but not in non-melancholic major depression. Journal of Affective Disorders, 2001, 66, 89-93.	2.0	84
279	Detection of Facial Expressions of Emotions in Depression. Perceptual and Motor Skills, 2001, 92, 857-868.	0.6	123
280	Cytokine production in unmedicated and treated schizophrenic patients. NeuroReport, 2000, 11, 3385-3388.	0.6	37
281	20â€Item Toronto Alexithymia Scale: Do difficulties describing feelings assess proneness to shame instead of difficulties symbolizing emotions?. Scandinavian Journal of Psychology, 2000, 41, 329-334.	0.8	48
282	The cerebral hemodynamics of repetitive transcranial magnetic stimulation. European Archives of Psychiatry and Clinical Neuroscience, 2000, 250, 320-324.	1.8	28
283	Psychosomatische Störungen bei Müttern. Psychotherapeut, 2000, 45, 10-17.	0.1	4
284	Eye-tracking dysfunction (ETD) in families with sporadic and familial schizophrenia. Biological Psychiatry, 2000, 47, 391-401.	0.7	49
285	A combined functional in vivo measure for primary and secondary auditory cortices. Hearing Research, 2000, 148, 153-160.	0.9	83
286	Elevated plasma levels of S-100b protein in schizophrenic patients. Biological Psychiatry, 1999, 45, 1508-1511.	0.7	95
287	Smooth pursuit performance in families with multiple occurrence of schizophrenia and nonpsychotic families. Biological Psychiatry, 1999, 45, 694-703.	0.7	19
288	Slow EEG potentials (contingent negative variation and post-imperative negative variation) in schizophrenia: their association to the present state and to Parkinsonian medication effects. Clinical Neurophysiology, 1999, 110, 1175-1192.	0.7	48

#	Article	IF	CITATION
289	Depression and social functioning in general hospital in-patients. Journal of Psychosomatic Research, 1998, 45, 117-126.	1.2	24
290	Distinguishing schizophrenic patients from healthy controls by quantitative measurement of eye movement parameters. Biological Psychiatry, 1998, 44, 448-458.	0.7	32
291	Increased serum neopterin levels in acutely ill and recovered schizophrenic patients. Schizophrenia Research, 1998, 32, 63-67.	1.1	29
292	Backward masking in schizophrenia: time course of visual processing deficits during task performance. Schizophrenia Research, 1998, 33, 79-86.	1.1	17
293	Immunological Dysfunction in Schizophrenia: A Systematic Approach. Neuropsychobiology, 1998, 37, 186-193.	0.9	93
294	Relations between Neuropsychological Vulnerability Markers and Negative Symptoms in Schizophrenia. Psychopathology, 1998, 31, 178-187.	1.1	18
295	The Lý beck General Hospital Study. I: Prevalence of psychiatric disorders in medical and surgical inpatients. International Journal of Psychiatry in Clinical Practice, 1997, 1, 207-216.	1.2	36
296	Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Research, 1997, 66, 145-152.	1.7	45
297	Paranoid schizophrenia: non-specificity of neuropsychological vulnerability markers. Psychiatry Research, 1997, 72, 103-114.	1.7	17
298	Production of cytokines in acute schizophrenic psychosis. Biological Psychiatry, 1996, 40, 1294-1297.	0.7	67
299	Alcoholism and psychiatric comorbidity in general hospital inpatients. General Hospital Psychiatry, 1996, 18, 271-277.	1.2	45
300	Increased CD56+Natural Killer Cells and Related Cytokines in Major Depression. Clinical Immunology and Immunopathology, 1996, 78, 83-85.	2.1	100